The estimated Net Worth of Mary Tedd Allen is at least $1.2 millió dollars as of 1 July 2019. Dr Allen owns over 64,333 units of Nanostring Technologies Inc stock worth over $9,979 and over the last 11 years he sold NSTG stock worth over $1,189,352.
Dr has made over 6 trades of the Nanostring Technologies Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 64,333 units of NSTG stock worth $1,014,531 on 1 July 2019.
The largest trade he's ever made was exercising 64,333 units of Nanostring Technologies Inc stock on 1 July 2019 worth over $1,014,531. On average, Dr trades about 9,096 units every 15 days since 2013. As of 1 July 2019 he still owns at least 94,766 units of Nanostring Technologies Inc stock.
You can see the complete history of Dr Allen stock trades at the bottom of the page.
Dr. Mary Tedd Allen is the Sr. VP of Strategic Initiatives at Nanostring Technologies Inc.
Dr Allen is 58, he's been the Sr. VP of Strategic Initiatives of Nanostring Technologies Inc since . There are 9 older and 8 younger executives at Nanostring Technologies Inc. The oldest executive at Nanostring Technologies Inc is William Young, 75, who is the Independent Chairman of the Board.
Mary's mailing address filed with the SEC is 530 Fairview Ave N, Seattle, WA 98109, USA.
Over the last 11 years, insiders at Nanostring Technologies Inc have traded over $114,083,977 worth of Nanostring Technologies Inc stock and bought 981,722 units worth $9,126,410 . The most active insiders traders include Charles P Jr Waite, Lifesciences Ii, L.P.Clarus... és Nicholas Galakatos. On average, Nanostring Technologies Inc executives and independent directors trade stock every 16 days with the average trade being worth of $4,371. The most recent stock trade was executed by Joseph M Beechem on 6 May 2024, trading 147,853 units of NSTG stock currently worth $15,569.
nanostring technologies (nasdaq: nstg) is a publicly held provider of life science tools for translational research and molecular diagnostics. the company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. nanostring technologies provides life science tools for translational research and molecular diagnostic products. the company's ncounter® analysis system, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the ncounter dx analysis system. the company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, mirnas, or copy number variations, simultaneously with high sensitivity and precision. the company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and vali
Nanostring Technologies Inc executives and other stock owners filed with the SEC include: